Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2003 1
2004 1
2006 2
2007 3
2008 16
2009 41
2010 37
2011 28
2012 45
2013 57
2014 66
2015 60
2016 37
2017 21
2018 7
2019 1
2020 1
2021 2
2022 2
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

384 results

Results by year

Filters applied: . Clear all
Page 1
Chelation of Mitochondrial Iron as an Antiparasitic Strategy.
Arbon D, Mach J, Čadková A, Sipkova A, Stursa J, Klanicová K, Machado M, Ganter M, Levytska V, Sojka D, Truksa J, Werner L, Sutak R. Arbon D, et al. ACS Infect Dis. 2024 Feb 9;10(2):676-687. doi: 10.1021/acsinfecdis.3c00529. Epub 2024 Jan 30. ACS Infect Dis. 2024. PMID: 38287902 Free PMC article.
Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.
Park HA, Edelmann D, Canzian F, Seibold P, Harrison TA, Hua X, Shi Q, Silverman A, Benner A, Macauda A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Park HA, et al. Int J Cancer. 2023 Nov 1;153(9):1623-1634. doi: 10.1002/ijc.34663. Epub 2023 Aug 4. Int J Cancer. 2023. PMID: 37539667
Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis.
Park HA, Edelmann D, Canzian F, Harrison TA, Hua X, Shi Q, Silverman A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Park HA, et al. Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2087-2091. doi: 10.1158/1055-9965.EPI-22-0320. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35984985 Free PMC article. Clinical Trial.
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Morgans AK, Chen YH, Jarrard DF, Carducci M, Liu G, Eisenberger M, Plimack ER, Bryce A, Garcia JA, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, DiPaola RS, Cella D, Sweeney CJ; ECOG-ACRIN E3805 Investigators. Morgans AK, et al. Prostate. 2022 Sep;82(12):1176-1185. doi: 10.1002/pros.24369. Epub 2022 May 10. Prostate. 2022. PMID: 35538398 Free PMC article. Clinical Trial.
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
Wang V, Geybels MS, Jordahl KM, Gerke T, Hamid A, Penney KL, Markt SC, Freedman M, Pomerantz M, Lee GM, Rana H, Börnigen D, Rebbeck TR, Huttenhower C, Eeles RA, Stanford JL, Consortium P, Berndt SI, Claessens F, Sørensen KD, Park JY, Vega A, Usmani N, Mucci L, Sweeney CJ. Wang V, et al. Prostate. 2021 Jul;81(10):683-693. doi: 10.1002/pros.24148. Epub 2021 May 6. Prostate. 2021. PMID: 33956343 Free PMC article.
384 results